AMT-253 in Patients With Selected Advanced Solid Tumours

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

Key facts

Study ID

NCT05906862

Run by

Multitude Therapeutics (Australia) Pty Ltd

People needed

54

Starts

2023-11-06

Expected to finish

2026-12-30

Last updated by the study team

2025-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Blacktown — Sydney, New South Wales, Australia (enrolling)
• Chris O'Brien Lifehouse — Sydney, New South Wales, Australia (enrolling)
• Maquarie University Hospital — Sydney, New South Wales, Australia (enrolling)
• ICON Cancer Centre — Brisbane, Queensland, Australia (enrolling)
• Southern Oncology Clinical Research — Adelaide, South Australia, Australia (enrolling)
• Cabrini Malvern Hospital — Malvern, Victoria, Australia (enrolling)
• Alfred Hospital — Melbourne, Victoria, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.